Drug Database
MF

MF-59 (MF59)

✓ Approved

Novartis AG · 小分子 · 小分子

什么是 MF-59?

MF-59 是一种小分子,由Novartis AG研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)。

药物档案

商品名MF59
公司Novartis AG
药物类别小分子
给药途径Injectable (Others)
状态Approved

治疗适应症

MF-59 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Surgical and medical proceduresOral appliance application✓ Approved

相关研究文献

PubMedGenomics, proteomics & bioinformatics2026-11-20

MF-PENS: An Efficient and Versatile Nuclear Extraction Method for Plant Single-cell Sequencing.

Du Lin L, Liu Qing Q, Zhou Hongling H, Zhao Mengyue M et al.

The widespread adoption of single-cell transcriptomics in plants remains constrained by the challenges of isolating high-quality nuclei from tissues with rigid cell walls and complex metabolomes. Here, we present methanol fixation and percoll-enriched nuclei sorting (MF-PENS), a robust strategy designed to tackle these limitations. Distinct from conventional protocols, MF-PENS circumvents the need for fluorescence activated nuclei sorting (FANS) and effectively reduces RNA leakage, consistently yielding high-quality single-nucleus RNA sequencing (snRNA-seq) data. MF-PENS has been validated across various plant tissues, including fresh and frozen rice roots and leaves, as well as recalcitrant samples such as soybean root nodules, soybean seeds, and tomato fruits. Benchmarking results demonstrate that MF-PENS significantly enhances gene capture efficiency, cell clustering performance, and cell type annotation accuracy. With its broad applicability and superior performance, MF-PENS represents a robust and versatile tool for plant single-cell research, facilitating deeper insights into plant development and biological processes.

PMID 43058985
阅读全文 →
PubMedBMC cancer2026-11-20

Perceived and experienced impacts of anemia and transfusion dependence in myelofibrosis: a mixed-methods study.

Cardellino Anna A, Collacott Hannah H, Zhang Shiyuan S, Turner Vicky V et al.

Myelofibrosis (MF) is a rare myeloproliferative neoplasm characterized by bone marrow fibrosis, anemia, splenomegaly, and debilitating symptoms. Anemia, present in approximately 35% of patients at diagnosis, often worsens over time and is associated with poor quality of life and worsened survival outcomes. Red blood cell transfusions help to manage anemia but are burdensome and may lead to iron overload. Existing literature focuses on clinical outcomes, and little is known about patient-perceived and -experienced impacts of transfusion and anemia. This mixed-methods study across 6 countries included qualitative interviews and an online survey of symptomatic (Myelofibrosis Symptom Assessment Form v4.0 Total Symptom Score ≥ 10) adults with MF with prior Janus kinase inhibitor experience, including both transfusion-dependent (TD) and transfusion-independent (TI) patients. Twenty participants (5 TD, 15 TI) completed interviews to inform an online survey fielded among 155 (76 TD, 51 TI, 28 transfusion-naive) participants. Questions assessed perceived and experienced burdens and impacts of anemia and transfusions. Concept elicitation interviews (N = 20) identified safety (85%), convenience (85%), and travel requirements (60%) as top concerns associated with transfusions; 40% noted symptom relief from transfusions, and 90% valued treatments to control anemia and reduce transfusion need. Across online survey participants (N = 155), fatigue (85.2%), weakness (72.9%), and headaches (47.7%) were the most frequently reported symptoms, with negative impacts to daily activities (73%), physical activities (56%), ability to think (54%), and emotional health (53%). Transfusion-related inconveniences included time spent at the clinic (81%), travel time (40%), and scheduling issues (32%). The most burdensome impacts of transfusions were to daily activities (55.5%), emotional health (52.3%), and family responsibilities (35.5%). Among TD participants, 52.2% rated reducing their needed transfusion frequency as "extremely important," although some acknowledged benefits associated with symptom relief. This study underscores the significant symptom burden of anemia and the broad impacts of transfusion dependence in MF. Qualitative and quantitative findings reveal emotional, physical, and logistical challenges associated with transfusions and patients' strong desire to minimize their frequency. Results support the development of patient-centered therapies that improve anemia and reduce transfusions, addressing key medical needs in MF management.

PMID 43058551
阅读全文 →
PubMedOrphanet journal of rare diseases2026-11-20

A qualitative study assessing content validity of Neuro-QoL fatigue and PROMIS mental fatigue in m.3243A>G primary mitochondrial disease.

Smeitink Jan J, Hoogstraten Charlotte A CA, Janssen Mirian C H MCH, Renkema Herma H et al.

Fatigue is frequently reported and clinically significant in m.3243A > G primary mitochondrial disease (PMD) patients, hereafter PMD. This study aimed to understand the lived experience of PMD from the patient's perspective with a particular focus on fatigue, and to explore the content validity of an existing measure of fatigue, the Neuro-QoL short form version 1 - Fatigue (Neuro-QoL SFv1-F). Genetically confirmed PMD patients were recruited from the USA and the Netherlands. Eighteen participants took part in concept elicitation (CE) interviews. Seventeen participants, three of whom had not taken part in the CE interviews, took part in cognitive debrief (CD) interviews. Some participants took part in both interviews, whilst others participated in only a CE or CD interview. CE interviews explored participants' lived experience of symptoms and impacts, with a focus on fatigue, while CD interviews explored participants' understanding of the measures. Interview transcripts were analyzed using thematic analysis. Following CE interviews, characteristics of fatigue were mapped to the Neuro-QoL SFv1-F items to assess whether the measure comprehensively captured the lived experience of PMD-related fatigue. This study included 21 adult PMD participants (age 46.3 ± 9.3 years, 81% female, and 52.4% had moderate clinician-reported disease severity). CE interviews identified 21 signs and symptoms of PMD, with physical and mental fatigue, hearing loss, and pain most frequently reported and described as bothersome. Impacts included reduced physical functioning, emotional impacts, affected social life, and work or school impacts, with a reliance on assistance from others. Item mapping showed that the Neuro-QoL SFv1-F captured core physical fatigue concepts but did not adequately capture mental fatigue. To address this gap, a new measure, the PROMIS Mental Fatigue Mitochondrial Disease Short Form (PROMIS MF-MD SF), was developed. Cognitive debriefing of the Neuro-QoL SFv1-F and the PROMIS MF-MD SF confirmed that the measures were understandable and relevant to patients with suitable response options. Participants discussed that they felt a 1-category improvement or worsening on any item of the Neuro-QoL SFv1-F and PROMIS MF-MD SF meaningful. This study provides support for the content validity and suitability of the Neuro-QoL SFv1-F and PROMIS MF-MD SF in adults with PMD. Not applicable.

PMID 43058735
阅读全文 →
PubMedPreventive medicine reports2026-11-20

Cardiovascular risk factors and awareness among adults attending an opportunistic community screening event in Réunion Island.

Pokeerbux Mohammad Ryadh MR, Fortune Gaspard G, Nobecourt Estelle E, Patel Fowzia F et al.

To describe cardiovascular risk factors and their awareness among adults attending a community screening event in Réunion Island, a French overseas department with a high cardiometabolic burden. On May 26, 2026, free voluntary screening was offered to adults on the Saint-Pierre seafront, Réunion Island, France. Cardiovascular history, risk factors, treatments, and awareness of cardiovascular risk factors were self-reported through brief verbal questions. Blood pressure, capillary glucose, and lipids (point-of-care analyzer) were measured. Hypertension, diabetes, and dyslipidemia were defined by previous diagnosis, current treatment, or predefined screening thresholds. Forty-one adults were screened (median age, 54.0 years [interquartile range, 40.0-70.0]; 59% men). Five (12%) had a history of cardiovascular disease, and 23 (56%) reported being unaware of cardiovascular risk factors. Hypertension and dyslipidemia were each identified in 18 participants (44%; 95% CI 30, 59) and diabetes in 9 (22%; 95% CI 12, 37). Blood pressure was controlled in five of nine (56%) treated participants. Participants had a high burden of cardiovascular risk factors and limited awareness of them. Although based on a small, self-selected sample, these findings are consistent with the known cardiometabolic burden of Réunion Island and support community screening and education to complement routine prevention.

PMID 43061187
阅读全文 →
PubMedResearch square2026-11-20

Quantification of domain-specific intrinsic capacity using mortality data.

Fuentealba Matías M, Belic Minja M, Zhai Ting T, Dajani Saleem A Al SAA et al.

Functional health is centered on five domains of Intrinsic Capacity (IC): locomotion, cognition, vitality, psychological and sensory capacity. Therefore, measuring IC at the domain-specific level is the cornerstone for developing preventive interventions to help individuals preserve their independence. In this study, we used 59 clinical features from the UK Biobank to develop 'Functional age', an 18-year mortality risk estimator associated with the decline of each IC domain. By establishing proteomic surrogates of Functional age, we find immune system activation across domains and provide a proteomic framework that may facilitate scalable monitoring of functional health decline.

PMID 43060347
阅读全文 →
PubMedPopulation health metrics2026-11-20

Hidden alcohol- attributable mortality in Russia: evidence from regional panel data, 2000-2019.

Shchur Aleksey A, Shkolnikov Vladimir M VM, Rodina Olga O, Sergeev Egor E et al.

Alcohol has long been a major driver of low life expectancy in Russia. Changes in life expectancy have shown a strong negative temporal correlation with mortality from alcohol poisoning; however, the total burden of alcohol‑attributable mortality has been difficult to assess, since many such deaths are not explicitly recorded as alcohol‑related. This study aimed to estimate hidden alcohol-attributable mortality in addition to mortality directly attributed to alcohol in death certificates. Data from Russian regions were analysed separately for men and women aged 20-59 years from 2000 to 2019. Fixed-effects panel regression models examined the relationship between mortality from alcohol poisoning, used as a proxy for hazardous drinking, and mortality from causes not certified as alcohol-related. Mortality associated with alcohol poisoning was interpreted as hidden alcohol-attributable mortality. Total alcohol-attributable mortality was estimated as the sum of certified and hidden alcohol-attributable mortality. Mortality from alcohol poisoning was strongly associated with mortality from causes not certified as alcohol-related. Each additional death per 100,000 from alcohol poisoning was associated with increases of 7.3 deaths per 100,000 among men and 5.7 among women (p < 0.01). Total alcohol-attributable mortality peaked in the early 2000s and declined thereafter. By 2019, it accounted for approximately 30% of deaths among men and 17% among women aged 20-59 years. Despite improvements in life expectancy prior to the COVID-19 pandemic, alcohol continues to contribute substantially to premature mortality in Russia. Many alcohol-attributable deaths may be hidden within causes not certified as alcohol-related, suggesting that the burden of alcohol-related mortality remains underestimated.

PMID 43058762
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多MF-59